ArticleThe Journal of biological chemistry2026
Tryptophan metabolites 3-hydroxykynurenine (3HK) and 3-hydroxyanthranilic acid (3HAA) increase oxidative stress and impair osteoblastic bone formation.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
The aryl hydrocarbon receptor (AhR) is activated by kynurenine (Kyn), a tryptophan metabolite that accumulates with age, and this process drives osteoblast dysfunction. However, Kyn can be further metabolized, and the extent to which downstream metabolite molecules activate AhR in mesenchymal lineage cells and impact bone formation activity was unclear from previous studies. We hypothesized that Kyn metabolites activate AhR signaling and impair bone formation to drive bone loss. In the current study, tryptophan, Kyn, and 3-hydroxy-kynurenine (3HK) dose-dependently activated AhR in mesenchymal stem cell models, with 3HK being the most potent activator. Treating mesenchymal stem cells with 3HK and 3-hydroxyanthranilic acid (3HAA) dose-dependently induced DNA damage that at lower concentrations induced senescence and at higher concentrations promoted apoptotic cell death. This cell death was rescued upon scavenging reactive oxygen species with N-acetylcysteine, suggesting a mechanism of apoptosis related to increased oxidative stress. With regards to bone formation activity, the differentiation of primary bone marrow stromal cells into matrix-producing osteoblasts was blunted upon the introduction of Kyn, 3HK or 3HAA into osteogenic differentiation media, with 3HK and 3HAA inducing the greatest deficits in mineralized matrix production. In vivo administration of 3HAA to C57BL/6 mice was detrimental to whole-body bone mineral density and cortical bone mass, although trabecular bone was largely unaffected. Together, our results suggest that several intermediate metabolites in the tryptophan-Kyn pathway activate AhR and impede the differentiation of osteoblasts by inducing DNA damage, senescence and oxidative stress, which may have negative consequences for cortical bone in vivo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.